Mar 26, 2025 09:05AM

Mar 26, 2025 09:05AM

Feb 13, 2025 08:00AM

Dec 17, 2024 08:50AM

Dec 4, 2024 09:20AM

Aug 19, 2024 08:45AM

Aug 19, 2024 08:45AM Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pan

Dec 14, 2023 04:15PM

Oct 31, 2023 07:32AM

Oct 31, 2023 07:30AM

Aug 16, 2023 07:31AM

Aug 16, 2023 07:30AM

May 10, 2022 08:15AM

Mar 16, 2022 07:01AM Sonnet BioTherapeutics (SONN) Granted FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors

Mar 16, 2022 07:00AM

Feb 8, 2022 07:00AM

Dec 17, 2021 06:33AM

Dec 17, 2021 06:30AM

Aug 31, 2021 09:19AM

Aug 16, 2021 06:30AM

May 10, 2021 06:30AM Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)

Mar 29, 2021 04:30PM

Mar 22, 2021 07:00AM

Feb 16, 2021 08:10AM

Nov 30, 2020 08:30AM

Aug 24, 2020 09:31AM

Aug 24, 2020 08:41AM

Apr 2, 2020 02:16AM RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All